CRISPR THERAPEUTICS AG (CRSP) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
44/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCRSP / S&P 14.65% / 15.20% |
LoseCRSP / S&P -64.80% / 15.00% |
LoseCRSP / S&P -12.38% / 50.40% |
| 2026-Q11/3 |
LoseCRSP / S&P -9.29% / -4.33% |
LoseCRSP / S&P -89.11% / 11.30% |
WinCRSP / S&P 37.78% / 27.70% |
| 2025-Q41/3 |
LoseCRSP / S&P -19.09% / 2.65% |
LoseCRSP / S&P -90.59% / 9.00% |
WinCRSP / S&P 49.43% / 13.40% |
| 2025-Q32/3 |
WinCRSP / S&P 33.24% / 8.12% |
LoseCRSP / S&P -81.10% / 4.61% |
WinCRSP / S&P 98.93% / 13.45% |
| 2025-Q22/3 |
WinCRSP / S&P 42.93% / 10.94% |
LoseCRSP / S&P -81.18% / 4.83% |
WinCRSP / S&P 69.06% / 10.63% |
| 2025-Q11/3 |
LoseCRSP / S&P -13.54% / -4.27% |
LoseCRSP / S&P -86.13% / 4.98% |
WinCRSP / S&P 67.29% / 10.57% |
| 2024-Q41/3 |
LoseCRSP / S&P -16.22% / 2.41% |
LoseCRSP / S&P -89.95% / 5.25% |
WinCRSP / S&P 125.39% / 6.15% |
| 2024-Q31/3 |
LoseCRSP / S&P -13.02% / 5.89% |
WinCRSP / S&P 19.31% / 5.89% |
LoseCRSP / S&P -37.22% / 6.11% |
| 2024-Q21/3 |
LoseCRSP / S&P -20.76% / 4.28% |
WinCRSP / S&P 18.89% / 5.38% |
LoseCRSP / S&P -39.51% / 5.12% |
| 2024-Q11/3 |
LoseCRSP / S&P 8.88% / 10.56% |
WinCRSP / S&P 171.01% / 5.71% |
LoseCRSP / S&P -59.91% / 5.59% |
| 2023-Q42/3 |
WinCRSP / S&P 37.92% / 11.69% |
WinCRSP / S&P 30885.48% / 6.81% |
LoseCRSP / S&P -76.91% / 7.78% |
| 2023-Q31/3 |
LoseCRSP / S&P -19.15% / -3.27% |
WinCRSP / S&P 1106.49% / 7.52% |
LoseCRSP / S&P -48.74% / -5.03% |
| 2023-Q22/3 |
WinCRSP / S&P 24.12% / 8.74% |
WinCRSP / S&P 1047.70% / 9.50% |
LoseCRSP / S&P -34.93% / -8.57% |
| 2023-Q11/3 |
WinCRSP / S&P 11.27% / 7.50% |
LoseCRSP / S&P -89.05% / 10.77% |
LoseCRSP / S&P -280.86% / -15.69% |
| 2022-Q40/3 |
LoseCRSP / S&P -37.80% / 7.56% |
LoseCRSP / S&P -99.87% / 11.88% |
LoseCRSP / S&P -284.96% / -17.99% |
| 2022-Q31/3 |
WinCRSP / S&P 7.54% / -4.88% |
LoseCRSP / S&P -98.44% / 13.47% |
LoseCRSP / S&P -283.54% / -1.41% |
| 2022-Q21/3 |
WinCRSP / S&P -3.19% / -16.10% |
LoseCRSP / S&P -98.36% / 13.71% |
LoseCRSP / S&P -259.72% / 11.04% |
| 2022-Q11/3 |
LoseCRSP / S&P -17.17% / -4.60% |
WinCRSP / S&P 83039.33% / 15.97% |
LoseCRSP / S&P -165.66% / 42.23% |
| 2021-Q41/3 |
LoseCRSP / S&P -32.30% / 11.03% |
WinCRSP / S&P 127154.94% / 15.00% |
LoseCRSP / S&P -185.44% / 96.40% |
| 2021-Q31/3 |
LoseCRSP / S&P -30.86% / 0.58% |
WinCRSP / S&P 1066.46% / 10.77% |
LoseCRSP / S&P -245.85% / 69.42% |
| 2021-Q23/3 |
WinCRSP / S&P 32.86% / 8.55% |
WinCRSP / S&P 211.87% / 6.58% |
WinCRSP / S&P 982.98% / 51.81% |
| 2021-Q10/3 |
LoseCRSP / S&P -20.42% / 6.17% |
LoseCRSP / S&P -99.62% / -1.06% |
LoseCRSP / S&P CRSP unavailable / 7.39% |
| 2020-Q41/3 |
WinCRSP / S&P 83.06% / 12.15% |
LoseCRSP / S&P -99.75% / -3.72% |
LoseCRSP / S&P CRSP unavailable / -33.42% |
| 2020-Q31/3 |
WinCRSP / S&P 13.81% / 8.93% |
LoseCRSP / S&P -63.63% / -2.04% |
LoseCRSP / S&P CRSP unavailable / -27.10% |
| 2020-Q22/3 |
WinCRSP / S&P 73.28% / 20.54% |
WinCRSP / S&P 21738.75% / -0.46% |
LoseCRSP / S&P CRSP unavailable / -27.11% |
| 2020-Q11/3 |
LoseCRSP / S&P -30.37% / -19.60% |
WinCRSP / S&P 13721.35% / 3.47% |
LoseCRSP / S&P CRSP unavailable / -14.75% |
| 2019-Q42/3 |
WinCRSP / S&P 48.59% / 9.07% |
WinCRSP / S&P 9169.85% / 5.36% |
LoseCRSP / S&P CRSP unavailable / 2.99% |
| 2019-Q31/3 |
LoseCRSP / S&P -12.97% / 1.70% |
WinCRSP / S&P 501.94% / 5.02% |
LoseCRSP / S&P CRSP unavailable / 0.21% |
| 2019-Q21/3 |
WinCRSP / S&P 31.86% / 4.30% |
LoseCRSP / S&P -96.44% / 6.64% |
LoseCRSP / S&P CRSP unavailable / 8.65% |
| 2019-Q11/3 |
WinCRSP / S&P 25.03% / 13.65% |
LoseCRSP / S&P -94.72% / 8.12% |
LoseCRSP / S&P CRSP unavailable / 14.29% |
| 2018-Q40/3 |
LoseCRSP / S&P -35.58% / -13.52% |
LoseCRSP / S&P -92.38% / 9.05% |
LoseCRSP / S&P CRSP unavailable / 18.23% |
| 2018-Q31/3 |
LoseCRSP / S&P -24.52% / 7.71% |
WinCRSP / S&P 220.75% / 10.21% |
LoseCRSP / S&P CRSP unavailable / 19.06% |
| 2018-Q22/3 |
WinCRSP / S&P 28.55% / 3.43% |
WinCRSP / S&P 265.08% / 9.03% |
LoseCRSP / S&P CRSP unavailable / 14.46% |
| 2018-Q12/3 |
WinCRSP / S&P 94.68% / -0.76% |
WinCRSP / S&P 436.49% / 7.68% |
LoseCRSP / S&P CRSP unavailable / 12.46% |
| 2017-Q42/3 |
WinCRSP / S&P 31.39% / 6.64% |
WinCRSP / S&P 693.90% / 7.03% |
LoseCRSP / S&P CRSP unavailable / 13.82% |
| 2017-Q31/3 |
WinCRSP / S&P 11.55% / 4.48% |
LoseCRSP / S&P CRSP unavailable / 5.68% |
LoseCRSP / S&P CRSP unavailable / 17.57% |
| 2017-Q20/3 |
LoseCRSP / S&P -26.41% / 3.09% |
LoseCRSP / S&P CRSP unavailable / 4.83% |
LoseCRSP / S&P CRSP unavailable / 17.74% |
| 2017-Q11/3 |
WinCRSP / S&P 7.45% / 6.07% |
LoseCRSP / S&P CRSP unavailable / 3.67% |
LoseCRSP / S&P CRSP unavailable / 13.32% |
| 2016-Q40/3 |
LoseCRSP / S&P CRSP unavailable / 3.82% |
LoseCRSP / S&P CRSP unavailable / 2.09% |
LoseCRSP / S&P CRSP unavailable / 7.05% |
| 2016-Q30/3 |
LoseCRSP / S&P CRSP unavailable / 3.85% |
LoseCRSP / S&P CRSP unavailable / 0.20% |
LoseCRSP / S&P CRSP unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CRSP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 14.55% | 20.78% |
| Annualized return | 14.55% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CRSP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -53.02% | 83.14% |
| Annualized return | -14.02% | 12.86% |
10Y · 2016-10-19 to 2026-08-27
| Metric | CRSP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 321.36% | 319.30% |
| Annualized return | 15.47% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |